About: Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.40 (-3.13%)
IPSC NASDAQ Century Therapeutics Inc
Century Therapeutics Inc share price
IPSC price activity
Last Price
$1.440
Change (24hr)
-0.03 USD (-2.04%)
Volume
390.77K
Volume (4w avg)
-
Open
$1.47
Day Range
$1.44 - $1.51
Previous Close
$1.47
Last Trade
12 Oct, 8:00 pm GMT+0
Delayed
12 Oct, 8:00 pm GMT+0
IPSC price performance
Delayed
12 Oct, 8:00 pm GMT+0
IPSC Market Signals